OneSource Specialty Pharma reported a robust 37.4% revenue growth and a 448% surge in profit for Q2 FY27. Despite the strong financials, the company faces a significant USD 136 million arbitration claim from Prestige Biopharma, which investors must monitor closely.
OneSource Specialty Pharma Q2 Profit Jumps 448% to Rs 574.84 Million
Revenue: Rs 5,162.42 Million | Profit: Rs 574.84 Million
Reader Takeaway: Strong operational growth is significantly outpaced by a massive USD 136 million arbitration claim, creating investor uncertainty.
What just happened
OneSource Specialty Pharma released its financial results for the quarter ending September 30, 2026. The company reported a substantial 37.4% year-on-year revenue growth to Rs 5,162.42 million. Net profit surged by 448.2% to Rs 574.84 million, compared to Rs 104.85 million in the same quarter last year.
Why this matters
The strong top-line growth indicates robust operational performance; however, the company disclosed a material litigation involving its subsidiary, Biolexis Pte Limited. The Singapore International Arbitration Centre (SIAC) is currently reviewing a claim of USD 136.32 million (Rs 13,083.99 million) filed by Prestige Biopharma Limited against Biolexis regarding the termination of a manufacturing agreement.
The backstory
The dispute stems from alleged issues regarding plant readiness and raw material supply chain challenges. Biolexis denies the liability and has initiated a counter-claim, seeking a full refund of a 'Capacity fee' amounting to USD 13.62 million (Rs 1,307.25 million) previously paid to the partner.
What changes now
Investors must account for the legal risk, as the potential liability exceeds the company's current quarterly profit significantly. Additionally, the company has reclassified Rs 3,676.84 million of borrowings from non-current to current liabilities following an MCA notification related to covenant waiver timings.
Risks to watch
The primary risk is the ongoing SIAC arbitration. An adverse ruling could impact the company's balance sheet significantly. The management maintains that the claims are frivolous, but legal proceedings remain inherently uncertain.
What to track next
Watch for further disclosures from the SIAC arbitration process and management commentary regarding the status of the manufacturing agreement dispute.